R&D Projects


Approach for personalized treatment of cancer patients through YAP-TEAD inhibitor.

The main objective of this project is to obtain a new innovative and effective anti-tumour drug, and to bring it to the market through a validated personalised medicine process, alongside a diagnostic tool to identify patients who may benefit from the therapy.

The first sub-objective of the project is to focus on the study of the efficacy of compounds with the highest cytotoxicity in screening assays using cell line libraries for three specific tumour types: NSCLC, TNBC, and malignant mesothelioma. These three tumour types, in which YAP1 alteration has been identified, belong to the group of tumours with the lowest five-year survival rate, which means that potential advances in the limited treatment options are vitally important for patients.


European companies participate in the project


The project aims to offer a new anti-tumour drug to patients with the lowest survival rate.

The project’s second sub-objective is to develop diagnostic tools to optimise the selection of eligible patients for therapy. To this end, efforts will focus on obtaining genomic signatures related to greater sensitivity or resistance to the compounds tested, and the validation of a new antibody for the detection and localisation of YAP1 through IHC and/or IF. In both cases, the end goal will be to obtain a Companion Kit that allows the identification of patients who may benefit from therapy by using validated methods and guidelines for the interpretation of the results for the analysis of YAP alterations.

To achieve the objectives


In order to successfully achieve this goal, a consortium has been formed consisting of three European SMEs. Inventiva brings its expertise in drug discovery, XenTech its skills in PDX model-based cancer drug efficacy studies, and Atrys its expertise in the field of immunohistochemistry and immunofluorescence.

This project has received funding from the Eurostars-2 joint programme, with co-funding from the CDTI and the European Union’s Horizon 2020 Framework Programme for Research and Innovation.

Financial blockers

Related projects



Sistema experto para diagnóstico y tratamiento personalizado en pacientes con cáncer

Read more


Inmunoterapias antitumorales de segunda generación: anticuerpos y nanobodies conjugados con toxinas mediante Inteínas-ZIP

Read more